RxDoctor Payments Data

Mark Peterman, MD

Interventional Cardiology · Plano, TXNPI 1386752939

Payments from drug & device makers

$20,787in general payments, 2019–2025

Across 825 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$2K
  • Abbott$2K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Amgen$1K
  • Medtronic$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$490%
  • Speaking & faculty fees$840%
  • Travel & lodging$9254%
  • Food & beverage$19,67595%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Heartflow, Inc.23$2,171
Abbott32$2,134
Johnson & Johnson107$1,797
Novartis76$1,323
Amgen88$1,241
Medtronic(2 entities)20$1,085
Pfizer56$1,025
Merck37$783
Sanofi30$710
E.r. Squibb & Sons, L.L.C.41$689
Abiomed9$552
Amarin Pharma, Inc.32$512
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)25$483
AstraZeneca24$482
Alnylam Pharmaceuticals Inc.21$467
Medicure Pharma Inc.3$446
Boehringer Ingelheim22$438
Esperion Therapeutics, Inc.23$376
Itamar Medical Inc5$367
Sanofi-aventis U.S. LLC23$366
Boston Scientific6$332
Cleerly, Inc.4$271
Lundbeck LLC13$215
Stryker3$178
Regeneron Healthcare Solutions, Inc.7$172
Scpharmaceuticals Inc.8$154
Recor Medical Inc3$150
Shockwave Medical, Inc2$132
Bridgebio Pharma, Inc.5$132
Arbor Pharmaceuticals, Inc.8$121
Bayer6$121
Imperative Care, Inc1$120
Kowa Pharmaceuticals America, Inc.7$105
Chiesi USA, Inc.5$90
Astellas Pharma US Inc4$83
Kiniksa Pharmaceuticals International, PLC3$78
W. L. Gore & Associates, Inc.1$78
Novo Nordisk3$76
Innovation Technologies Inc2$72
Althera Pharmaceuticals LLC6$69
Bard Peripheral Vascular, Inc.1$65
Angiodynamics, Inc.4$65
Tactile Systems Technology Inc4$61
Cvrx, Inc.2$53
Baxter Healthcare1$40
G Medical Diagnostic Services, Inc.2$28
Edwards Lifesciences2$26
Philips North America LLC1$24
Lexicon Pharmaceuticals, Inc.1$23
Lilly USA, LLC1$21
Atricure, Inc.1$20
Inari Medical, Inc.1$19
Azurity Pharmaceuticals, Inc.1$17
Kiniksa Pharmaceuticals, Ltd.1$17
GSK1$16
Inspire Medical Systems, Inc.1$15
Preventice Services, LLC1$15
Saranas, Inc.1$15
Surmodics, Inc.1$14
Bardy Diagnostics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,787 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$748,884
Medicare patients
1,296
Services billed
6,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban554$597,021
XareltoRivaroxaban139$147,286
Repatha SureclickEvolocumab89$95,383
EntrestoSacubitril/Valsartan64$71,453
BrilintaTicagrelor61$47,554
JardianceEmpagliflozin22$21,548
MultaqDronedarone Hcl11$15,436
Rosuvastatin Calcium553$7,496
Clonidine24$7,325
Metoprolol Succinate555$6,414
Atorvastatin Calcium417$4,219
ClopidogrelClopidogrel Bisulfate323$4,005
Nifedipine ErNifedipine126$3,861
Eplerenone35$3,095
Losartan Potassium335$2,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,025$597,021554 claims
Johnson & JohnsonXarelto$1,797$147,286139 claims
NovartisEntresto$1,323$71,45364 claims
AstraZenecaBrilinta$482$47,55461 claims
Boehringer IngelheimJardiance$438$21,54822 claims
Sanofi-aventis U.S. LLCMultaq$366$15,43611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →